| Title |
In Vitro Uses of Human Pluripotent Stem Cell-Derived Cardiomyocytes
|
|---|---|
| Published in |
Journal of Cardiovascular Translational Research, May 2012
|
| DOI | 10.1007/s12265-012-9376-5 |
| Pubmed ID | |
| Authors |
Elena Matsa, Chris Denning |
| Abstract |
Functional cardiomyocytes can be efficiently derived from human pluripotent stem cells (hPSCs), which collectively include embryonic and induced pluripotent stem cells. This cellular platform presents exciting new opportunities for development of pharmacologically relevant in vitro screens to detect cardiotoxicity, validate novel drug candidates in preclinical trials and understand complex congenital cardiovascular disorders, to advance current clinical therapies. Here, we discuss the progress and impediments the field has faced in using hPSC-derived cardiomyocytes for these in vitro applications, and highlight that rigorous protocol optimisation and standardisation, scalability and automation are remaining obstacles for the generation of pure, mature and clinically relevant hPSC cardiomyocytes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 55 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 25% |
| Researcher | 14 | 25% |
| Student > Bachelor | 8 | 14% |
| Student > Doctoral Student | 5 | 9% |
| Student > Postgraduate | 3 | 5% |
| Other | 8 | 14% |
| Unknown | 5 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 27 | 47% |
| Biochemistry, Genetics and Molecular Biology | 13 | 23% |
| Engineering | 5 | 9% |
| Medicine and Dentistry | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 6 | 11% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2021.
All research outputs
#6,750,519
of 22,665,794 outputs
Outputs from Journal of Cardiovascular Translational Research
#172
of 574 outputs
Outputs of similar age
#48,052
of 164,803 outputs
Outputs of similar age from Journal of Cardiovascular Translational Research
#3
of 12 outputs
Altmetric has tracked 22,665,794 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 574 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,803 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.